Non-ST Elevation Myocardial Infarction in the Elderly. Antithrombotic Therapy and Beyond

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 30

PMID 39077013

Authors

Pablo Diez-Villanueva

Cesar Jimenez-Mendez

Jose Luis Ferreiro

Pedro Cepas-Guillen

Clara Bonanad

Sergio Garcia-Blas

Albert Ariza-Sole

Juan Sanchis

Manuel Martinez-Selles

Affiliations

Soon will be listed here.

Abstract

Non-ST segment elevation myocardial infarction (NSTEMI) is the most frequent type of acute coronary syndrome in the elderly. Antithrombotic therapy is the cornerstone of pharmacological therapy in the setting of an acute ischemic event, a clinical scenario in which thrombotic and bleeding risks ought to be considered, particularly in older patients. In this article, specific aspects of antithrombotic therapy in elderly patients with NSTEMI are reviewed, including pharmacokinetic and pharmacodynamic characteristics and different clinical situations. The role of frailty and other common geriatric conditions, that are associated with worse prognosis in elderly patients with cardiovascular disease, is also addressed.

Citing Articles

Current Management of Non-ST-Segment Elevation Acute Coronary Syndrome.

Diez-Villanueva P, Jimenez-Mendez C, Cepas-Guillen P, Arenas-Loriente A, Fernandez-Herrero I, Garcia-Pardo H Biomedicines. 2024; 12(8).

PMID: 39200201 PMC: 11352006. DOI: 10.3390/biomedicines12081736.

The Impact of Geriatric Conditions in Elderly Patients with Coronary Heart Disease: A State-of-the-Art Review.

Alonso Salinas G, Cepas-Guillen P, Martinez Leon A, Jimenez-Mendez C, Lozano-Vicario L, Martinez-Avial M J Clin Med. 2024; 13(7).

PMID: 38610656 PMC: 11012545. DOI: 10.3390/jcm13071891.

References

Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y . P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021; 373:n1332. PMC: 8207247. DOI: 10.1136/bmj.n1332. View

Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S . Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet. 2016; 387(10023):1057-1065. DOI: 10.1016/S0140-6736(15)01166-6. View

Caldeira D, Nunes-Ferreira A, Rodrigues R, Vicente E, Pinto F, Ferreira J . Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr. 2019; 81:209-214. DOI: 10.1016/j.archger.2018.12.013. View

Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P . Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med. 2021; 385(18):1643-1655. DOI: 10.1056/NEJMoa2108749. View

Sanchis J, Ruiz V, Bonanad C, Valero E, Ruescas-Nicolau M, Ezzatvar Y . Prognostic Value of Geriatric Conditions Beyond Age After Acute Coronary Syndrome. Mayo Clin Proc. 2017; 92(6):934-939. DOI: 10.1016/j.mayocp.2017.01.018. View

Vicent L, Ariza-Sole A, Alegre O, Sanchis J, Lopez-Palop R, Formiga F . Octogenarian women with acute coronary syndrome present frailty and readmissions more frequently than men. Eur Heart J Acute Cardiovasc Care. 2018; 8(3):252-263. DOI: 10.1177/2048872618798226. View

Rodriguez-Queralto O, Formiga F, Lopez-Palop R, Marin F, Vidan M, Martinez-Selles M . FRAIL Scale also Predicts Long-Term Outcomes in Older Patients With Acute Coronary Syndromes. J Am Med Dir Assoc. 2019; 21(5):683-687.e1. DOI: 10.1016/j.jamda.2019.10.007. View

Bonanad C, Esteve-Claramunt F, Garcia-Blas S, Ayesta A, Diez-Villanueva P, Perez-Rivera J . Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes. J Clin Med. 2022; 11(11). PMC: 9181473. DOI: 10.3390/jcm11113008. View

Guerrero C, Ariza-Sole A, Formiga F, Martinez-Selles M, Vidan M, Aboal J . Applicability of the PRECISE-DAPT score in elderly patients with myocardial infarction. J Geriatr Cardiol. 2019; 15(12):713-717. PMC: 6330266. DOI: 10.11909/j.issn.1671-5411.2018.12.003. View

10.

Bonanad C, Garcia-Blas S, Torres Llergo J, Fernandez-Olmo R, Diez-Villanueva P, Ariza-Sole A . Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 10(22). PMC: 8618042. DOI: 10.3390/jcm10225268. View

11.

Castellano J, Pocock S, Bhatt D, Quesada A, Owen R, Fernandez-Ortiz A . Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022; 387(11):967-977. DOI: 10.1056/NEJMoa2208275. View

12.

Rao S, Kirsch B, Bhatt D, Budaj A, Coppolecchia R, Eikelboom J . A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation. 2022; 146(16):1196-1206. DOI: 10.1161/CIRCULATIONAHA.122.061612. View

13.

Pavasini R, Maietti E, Tonet E, Bugani G, Tebaldi M, Biscaglia S . Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. Cardiovasc Drugs Ther. 2019; 33(5):523-532. DOI: 10.1007/s10557-019-06911-y. View

14.

Ruiz Ortiz M, Muniz J, Rana Miguez P, Roldan I, Marin F, Esteve-Pastor M . Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2017; 20(10):1577-1583. DOI: 10.1093/europace/eux316. View

15.

Majithia A, Bhatt D . Novel Antiplatelet Therapies for Atherothrombotic Diseases. Arterioscler Thromb Vasc Biol. 2019; 39(4):546-557. PMC: 6445601. DOI: 10.1161/ATVBAHA.118.310955. View

16.

Capranzano P, Angiolillo D . Antithrombotic Management of Elderly Patients With Coronary Artery Disease. JACC Cardiovasc Interv. 2021; 14(7):723-738. DOI: 10.1016/j.jcin.2021.01.040. View

17.

Giallauria F, Di Lorenzo A, Venturini E, Pacileo M, DAndrea A, Garofalo U . Frailty in Acute and Chronic Coronary Syndrome Patients Entering Cardiac Rehabilitation. J Clin Med. 2021; 10(8). PMC: 8071180. DOI: 10.3390/jcm10081696. View

18.

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

19.

Erlinge D, Gurbel P, James S, Lindahl T, Svensson P, Ten Berg J . Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol. 2013; 62(7):577-83. DOI: 10.1016/j.jacc.2013.05.023. View

20.

Sanchis J, Garcia Acuna J, Raposeiras S, Barrabes J, Cordero A, Martinez-Selles M . Comorbidity burden and revascularization benefit in elderly patients with acute coronary syndrome. Rev Esp Cardiol (Engl Ed). 2020; 74(9):765-772. DOI: 10.1016/j.rec.2020.06.015. View